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Abstract	  	  
Mixed cryoglobulinemia syndrome (MCs) is an immune-complex-mediated 
systemic vasculitis, also called cryoglobulinemic vasculitis, involving skin, 
joints, peripheral nerves, and several internal organs. Hepatitis C virus (HCV) 
is recognised as the etiologic agent for the majority of MCs patients (MC), as 
well as of number of autoimmune-lymphoproliferative and neoplastic 
disorders. In this context, HCV-related MCs represents an important model of 
virus-driven autoimmunity/cancer in humans. With regard the therapeutic 
strategies of MCs we can treat these patients at different levels by means of 
etiological (antivirals), pathogenetic/symptomatic drugs (mainly 
immunosuppressors, corticosteroids, plasmapheresis). In the majority of 
individuals, MCs shows a mild, slow-progressive clinical course needing only 
symptomatic treatments, generally low doses of corticosteroids. Considering 
the etiopathogenesis of the disease, the eradication of HCV infection should 
be considered the gold standard in the treatment of MCs. The use of combined 
peg-interferon-α/ribavirin and/or novel antiviral drugs may lead to HCV 
eradication in a significant percentage of cases with possible remission of 
MCs. On the other hand, the presence of rapidly progressive, diffuse vasculitis 
with multiple organ involvement may be successfully treated with aggressive 
immunosuppressive and anti-inflammatory therapies, mainly based on 
cyclophosphamide or rituximab, high dose corticosteroids, and 
plasmapheresis. Moreover, sequential/combined antiviral or 
immunosuppressive treatments could represent an useful therapeutic strategy 
particularly in MCs patients with major clinical manifestations. In clinical 
practice, the treatment of MCs should be tailored for the single patient 
according to the severity of clinical symptoms. In all cases, a careful clinical 
monitoring of the disease is mandatory, with particular attention to neoplastic 
complications, such as B-cell lymphoma. The present review focuses on the 
different therapeutic strategies in patients with MCs, including the treatment 
of cryoglobulinemic skin ulcers, which represents one of the most 
discouraging complications of the disease.  
 
 Introduction. 
Cryoglobulinemia refers to a laboratory abnormality characterized by the 
presence in the serum of one or more immunoglobulins, which precipitate at 
temperatures below 37°C and re-dissolve on re-warming [1, 2]. It is usually 
classified into three subgroups according to Ig composition [3]: namely, type I 
cryoglobulins are single monoclonal immunoglobulins related to 
hematological disorders, often B-cell lymphoproliferation, and it is per se 
frequently asymptomatic. Mixed cryoglobulinemia type II (IgG + monoclonal 
IgM) or type III (IgG + polyclonal IgM) consists of polyclonal IgG with or 
without monoclonal IgM, respectively, which has rheumatoid factor activity 
[1-3]. Circulating mixed cryoglobulins are commonly detected in a number of 
infectious or systemic autoimmune/neoplastic disorders [2-5]. On the contrary, 
mixed cryoglobulinemia syndrome (MCs) is regarded as distinct disorder, 
which can be classified among systemic vasculitides, in the subgroup 
involving small-medium sized vessels; MCs and  cryoglobulinemic vasculitis 
(CV) are synonyms [5]. 
The histological hallmark of the disease is the leukocytoclastic vasculitis 
secondary to the vascular deposition of circulating cryo- and non-
cryoprecipitable immune-complexes and complement [5]. The immune-
mediated vasculitic lesions are responsible for different MCs clinical features, 
including cutaneous and visceral organ involvement [1-3, 5].   
The prevalence of MCs is geographically heterogeneous; the disease is more 
common in Southern Europe than in Northern Europe or Northern America [5, 
6]. It is considered to be a rare disorder, however, there are no adequate 
epidemiological studies regarding its overall prevalence, up to date. MCs is 
characterized by a clinical polymorphism, thus patients with vasculitis are 
often referred to different specialty centres, and a correct diagnosis might be 
delayed or overlooked entirely; for the same reasons, the true prevalence of 
MCs might be underestimated [2, 5]. Overall, MCs is more common in 
women than in men (female to male ratio of 3:1), while the disease onset is 
particularly common in the fourth-fifth decades and in older people, and rarely 
seen in the young people. From a clinico-pathogenetic point of view MCs 
could represents a crossroad between classical rheumatic/autoimmune 
diseases, such as rheumatoid arthritis and primary Sjögren's syndrome, and 
lymphoproliferative/neoplastic disorders [2, 5].  
 
 
Etiopathogenesis of MCs.  
A causative role of hepatitis C virus (HCV) in the large majority of patients 
has been definitely established on the basis of epidemiological, pathological, 
and laboratory studies [7-11]. The prevalence of serum anti-HCV antibodies 
and/or HCV RNA in patients with MCs varies from 70% to almost 100% 
among different patient populations [12-13]; this finding relegates the term 
‘essential’ MCs to a few patients [14]. The clinical development of MCs is 
closely linked to the natural history of chronic HCV infection; generally, this 
immunological disorder represents a late complication of viral infection. The 
appearance of different MCs phenotypes may be the result of genetic and/or 
environmental cofactors, which remain largely unknown [4, 5]. 
The etiopathogenetic cascade of MC and other HCV-related disorders is 
summarized in figure 1 (left).  
The production of different organ-specific and systemic disorders is probably 
a multifactorial and multistep process: the trigger factors include some 
infectious agents, mainly HCV, host genetic predisposition, and possible 
unknown environmental/toxic causes. Some HCV antigens, i.e. HCV core, 
envelop E2, NS3, NS4, NS5A proteins, may represent a chronic stimulus to 
lymphocytes through specific receptors, such as CD81 that may interact with 
the viral E2 [15-17]. Predisposing factors may include particular HLA alleles 
[18], metabolic and hormonal status of infected individuals. The result is a 
'benign' B-cell proliferation with a large autoantibody production, among 
which rheumatoid factor (RF), and cryo- and non-cryoprecipitable immune-
complexes (IC) [19]. These immunological abnormalities may be correlated 
with different organ and non-organ-specific autoimmune disorders, including 
the systemic manifestations of MCs. On the other side, the activation of Bcl2 
proto-oncogene, responsible for prolonged survival of B-lymphocytes, may be 
a precondition to other genetic aberrations, which ultimately may produce 
overt B-cell lymphomas and other malignant neoplasias [20, 21]. The 
appearance of different malignancies can be observed in a small but not 
negligible percentage of patients, usually late manifestation of chronic HCV 
infection with/without MCs [20, 22-25]. Both immune-mediated and 
neoplastic diseases show a clinico-serological and pathological overlap. More 
frequently, autoimmune organ-specific manifestations may precede the 
development of systemic conditions, which in same individuals may be 
complicated by malignancies (Fig.1 left). From the other side, it is possible to 
observe the appearance of some autoimmune manifestations in patients with 
malignancies [23]. On the whole, the proposed ‘HCV syndrome’ encompasses 
this multiform complex of HCV-related clinical manifestations, among which 
the MCs represents a crossing road between autoimmune and neoplastic 
disorders [26]. 
 
Clinical features.  
The MCs is clinically characterized by a triad -purpura, weakness, arthralgias-, 
present in the large majority of patients, and chronic hepatitis, 
membranoproliferative glomerulonephritis (MPGN), peripheral neuropathy, 
skin ulcers, diffuse vasculitis, and, less frequently, by lymphatic and hepatic 
malignancies [5; Fig. 2]. 
The presenting symptoms largely vary among patients with MCs. At the initial 
observation, patients show different clinico-serological patterns, ranging from 
apparently isolated serum mixed cryoglobulins to complete cryoglobulinemic 
syndrome (Fig. 2).  For a correct clinical classification we can regard the MCs 
as a combination of serological findings (mixed cryoglobulins with RF 
activity and frequent low C4) and clinico-pathological features (purpura, 
leukocytoclastic vasculitis with multiple organ involvement) [27]. While, 
serum mixed cryoglobulins can be more frequently found in asymptomatic 
chronically HCV-infected individuals [5]. Figure 2 shows the main clinical 
features of MCs. Cutaneous manifestations represent the most frequent 
features of the MCs [2, 5]; the hallmark is the orthostatic, generally 
intermittent purpura, ranging from sporadic isolated petechiae to severe 
vasculitic lesions, while torpid ulcers of the legs and malleolar areas may 
affect a significant percentage of patients (Fig. 3). 
MC patients may frequently develop a permanent ochreous coloration on the 
legs due to repeated episodes of purpura (Fig.3). Skin manifestations, in 
particular orthostatic purpura and ulcers, are the direct consequence of 
vasculitic lesions with the possible contribution of chronic venous 
insufficiency, physical stress, including prolonged standing, and/or muggy 
weather. The majority of MCs patients suffers from arthralgias, while clear 
clinical signs of synovitis, usually mild, non-erosive oligoarthritis, are quite 
rare [28, 29, Sebastiani et al in the present issue]. Peripheral neuropathy may 
complicate the clinical course of MCs, frequently  as mild sensory neuritis in 
about 80% of MCs patients [30, 31]; it is clinically characterized by 
paresthesias with painful and/or burning sensations in the lower limbs, often 
with nocturnal exacerbation. Therefore, the patients’ quality of life is often 
compromised because of the chronicity of these symptoms along with their 
scarce sensibility to therapeutic attempts. In a minority of cases peripheral 
neuropathy may be complicated by severe sensory-motor manifestations; in 
some subjects it may complicate the alpha-interferon treatment [32]. 
Dysarthria and hemiplegia, consequence of central nervous system 
involvement, are rarely reported [5], while it is often difficult to distinguish 
these symptoms from the possible concomitant atherosclerotic manifestations. 
Moreover, mild-to-moderate chronic hepatitis can be observed at any time 
during the natural history of the disease as expression of the underlying HCV 
infection. Chronic hepatitis may evolve to cirrhosis, and less frequently may 
be complicated by hepatocellular carcinoma [23, 33]. With regards the overall 
prognostic value of hepatic manifestations, the liver involvement in patients 
with MCs seems to be less severe if compared to HCV-related chronic 
hepatitis alone [2, 5]. Xerostomia and xerophthalmia are present in almost half 
MCs patients; however, only a few cases meet the current criteria for the 
classification of primary Sjögren's syndrome [34, 35]. Raynaud phenomenon 
is reported in about 25% of patients, as showed in Fig. 2. 
Membranoproliferative glomerulonephritis (MPGN) type 1 is an important 
organ involvement, which may severely affect the prognosis and survival of 
the disease [36, 37]. MC-related MPGN is a typical immune-complex-
mediated glomerulonephritis, although other immunological mechanisms have 
also been hypothesized. A widespread vasculitis involving medium-small 
sized arteries, capillaries and venules may develop in a small proportion of 
patients and may involve the skin, kidney, lungs, central nervous system, and 
gastrointestinal tract [2, 5, 38]. Interstitial lung involvement (mainly 
subclinical alveolitis) has been anecdotally observed in MCs as well as in 
patients with isolated HCV infection [2, 39]. From a practical point of view, 
there is no relationship between the severity/activity of clinical symptoms, 
such as glomerulonephritis, skin ulcers, or diffuse vasculitis and the serum 
levels of cryoglobulins and/or hemolytic complement [5]. Some 
endocrinological disorders may be observed in MCs, mainly autoimmune 
thyroiditis with subclinical hypothyroidism, thyroid cancer, and an increased 
incidence of diabetes mellitus type 2 [40-43]. B-cell lymphoma is the most 
frequent neoplastic manifestation complicating MCs [24]. This malignancy 
may be related to the peripheral B-lymphocyte expansion and ‘indolent’ 
lymphoid infiltrates observed in the liver and bone marrow of MCs patients 
[25]. Other neoplastic manifestations, i.e. hepatocellular carcinoma or 
papillary thyroid cancer, are less frequently observed [33, 42]. In this light, the 
MCs can be regarded as a pre-neoplastic condition; consequently, careful 
clinical monitoring is recommendable, even in the presence of mild MCs. Low 
complement activity is almost invariably detectable in MCs, with the typical 
pattern of low/undetectable C4 and normal C3 serum levels, regardless the 
disease activity (Fig. 2). Of interest, a sudden increase in C4 to abnormally 
high levels can be observed in MCs patients complicated by B-cell lymphoma 
[5].  
 
Treatment 	  
MCs is characterized by mild, slow progressive clinical course, but in a 
significant number of patients with moderate/severe cutaneous and/or visceral 
organ involvement the therapeutical approach may result particularly 
challenging, considering the complex etiopathogenesis and clinical 
polymorphism of the disease. A correct strategy should deal with three 
concomitant factors; namely, HCV infection, autoimmune, and pre-neoplastic 
alterations (Fig. 1). Figure 1 shows the main steps of the etiopathogenetic 
process, i.e. viral infection, B-lymphocyte proliferation, and cryoglobulinemic 
vasculitis (Fig. 1); accordingly, we can treat MCs patients at different levels 
by means of etiologic, pathogenetic, and/or symptomatic therapies [2, 5, 26]. 
Considering the HCV as triggering and possibly perpetuating agent of the 
MCs through a chronic stimulus on the immune-system, an attempt at HCV 
eradication treatment should be done in all patients with HCV-associated MCs 
[5, 44, 45; see also Zignego et al. in the present issue]. 
Initially, the treatment with Interferon alpha (IFNα) was associated with a 
relatively poor response and a high rate of disease relapses [46]. Combination 
therapy with IFNα plus ribavirin showed a greater antiviral efficacy with 
sustained virological response in a variable percentage of patients with chronic 
hepatitis C, as well as much better short- and long-term results in MCs 
patients than reported with IFNα monotherapy [46, 47]. However, the 
beneficial effect observed with IFNα and ribarivin is often transient and not 
rarely associated with important immune-mediated side effects such as 
peripheral sensory-motor neuropathy, thyroiditis, and rheumatoid-like 
polyarthritis [48]. It is possible that IFNα, both antiviral and 
immunomodulating agent, can trigger or exacerbate some symptoms in 
predisposed subjects, therefore IFNα therapy should be avoided at least in 
those patients with clinically evident peripheral neuropathy. The efficacy of 
antiviral therapy  progressively increased during the time with the introduction 
of Peg-IFN and RBV, and ultimately it became very promising with the novel 
combination therapies, including interferon-free drugs [49; see also Zignego et 
al. in the present issue]. The long-term effects of HCV eradication needs to be 
deeply investigated; particularly the outcome of HCV-related immunological 
alterations, including cryoglobulinemia and its clinical manifestations. 
Although anecdotal or limited to small patients’ series, preliminary 
observations suggest that the effects of HCV eradication on MCs remain quite 
unpredictable [50]. One of the possible factors could be the duration of the 
disease at the time of HCV eradication with self-perpetuating autoimmune 
mechanism underlying long-lasting MCs; therefore, it is possible to 
hypothesize a point of no return in the natural history of MCs. In the setting of 
HCV eradication, a recent study suggested that the presence of MCs may 
represent a negative prognostic factor of virological response, while the 
clearance of HCV may lead to persistent resolution or improvement of MCs 
[50]. The more recent use of triple therapy with Peg-IFNα, ribavirin, and a 
specifically targeted antiviral agent so called DAAs (i.e. Boceprevir, 
Telaprevir, Sofosbuvir) led to improve sustained virological response rates in 
patients infected with HCV genotype 1 [51]. Boceprevir-based therapy was 
reported as safe and effective in cryoglobulinemic patients [50; see also 
Zignego et al in the present issue],  while the use of sofosbovir produced still 
contrasting effects [52].   
Further studies are needed to confirm and clarify the activity of these IFN-free 
antiviral combination in larger series of MCs patients.  
Hopefully, a vaccine-based therapy [53] with recombinant HCV proteins in 
HCV-infected individuals could be able to prevent the progression of viral 
infection and possibly to interrupt the virus-driven autoimmune disease. 
Immunosuppression with rituximab or cyclophosphamide represents the 
pathogenetic treatment of  patients with MCs (Fig. 1 right and 4). These 
treatments include also steroids, low-antigen-content (LAC) diet, and plasma 
exchange  [2, 26, 46, 54, 55]. 
The immunosuppressive agents are typically reserved for patients with severe 
disease manifestations such as MPGN, sensory-motor neuropathy and life-
threatening complications. In these patients high dose corticosteroids and 
immunosuppressors has been used for the control of severe vasculitis lesions, 
alone or as sequential/combined therapy, while awaiting the generally slow 
response to antiviral treatments [46, 54-56].  
Low dose corticosteroids may help to control minor intermittent inflammatory 
symptoms such as sporadic purpura, arthralgia, weakness, mild peripheral 
sensory neuropathy [2, 13, 26]. 
Plasmapheresis represents a pathogenetic/symptomatic therapy by removing 
circulating immune-complexes, mainly cryoglobulins, complement, and other 
pro-inflammatory agents; it is particularly effective for rapidly progressive 
glomerulonephritis, sensory-motor neuropathy, diffuse vasculitis, and/or 
severe skin ulcers [2,  57]. Both traditional plasma exchange and double-
filtration plasma exchange, in combination with steroids and 
immunosuppressors may be able to markedly reduce the circulating immune-
complex levels with rapid symptom amelioration [2]. Immunosuppressors 
(rituximab or cyclophosphamide) may reinforce the beneficial effect of plasma 
exchange and also prevent the possible rebound phenomenon during the 
tapering of aphaeretic sessions [38, 46].  
LAC-diet can improve the clearance of circulating immune-complexes by 
restoring the activity of the reticule-endothelial system, overloaded by large 
amounts of circulating cryoglobulins [58]. This particular dietetic treatment is 
able to reduce the input of alimentary macromolecules crossing the mucosal 
barrier of the gut; some foods, particularly dairy products and eggs, present a 
potential antigenic activity, and consequently might be involved in the 
pathogenesis of some immune-mediated diseases. The reduction of the 
alimentary input of macromolecules directed to mononuclear phagocyte 
system may improve its function in those diseases characterized by abnormal 
endogenous production of immune-complexes responsible for organ damage, 
i.e. mixed cryoglobulinemia and other immune-complex mediated diseases. In 
patients with clinically mild MCs symptoms LAC-diet has been usefully 
employed with low dosage of steroids (6- methyl-prednisolone 2–4 mg/day), 
often sufficient to improve mild MCs manifestations (arthralgias, sporadic 
purpura) [2, 54]. 
Anti-CD20 monoclonal antibody (rituximab, RTX) represents the first-line 
immunosuppressive/immunomodulating treatment of HCV-related MCs 
during the last years considering its efficacy and safety [49, 55, 56, 59]. In the 
first reports, the main indication for RTX was the failure or intolerance to 
other treatments, and/or associated lymphoma [60, 61]. 
RTX may be usefully employed alone or in combination/sequence with Peg-
IFNα-ribavirin; in MCs patients, combined antiviral (boceprevir) and RTX 
treatment may be followed by complete remission of MCs manifestations and 
sustained virological response (see also Zignego et al. in this issue).  
 
Tailoring specific treatment strategies  
In clinical practice, the treatment of MCs should be tailored for the single 
patient according to the severity of clinical symptoms (Fig. 4). Clinically 
asymptomatic patients usually do not need any treatment, even in the presence 
of high levels of cryocrit. However, antiviral therapy might represent the 
etiological treatment also for patients with mild MCs manifestations, with the 
purpose to avoid the progression of the immunological disorder as well as of 
the most severe hepatic manifestations. Patients with mild or moderate disease 
(i.e. arthralgia, purpura, and/or mild sensory polyneuropathy) may be treated 
with low dose corticosteroids and/or LAC-diet able to control these minor 
inflammatory manifestations. On the contrary, sequential/combined antiviral 
and immunosuppressive therapy should be considered in patients with 
moderate-severe symptoms; an attempt with antivirals might be firstly used in 
subjects with active chronic hepatitis, with high risk to develop cirrhosis 
and/or hepatocellular carcinoma. Finally, patients with severe vasculitic 
manifestations, MPGN, sensory-motor neuropathy, and/or widespread 
vasculitis must be timely treated with high doses of steroids, plasma exchange, 
and/or cyclophosphamide or RTX. For the above manifestations the 
therapeutic strategy should be tailored on the single patient according to the 
variable combination of clinical symptoms and possible comorbidities (fig. 4, 
right). For MCs patients presenting with the fulminant clinical variants, 
including peripheral necrosis of extremities, rapidly progressive 
glomerulonephritis, abdominal, cardiac, pulmonary and/or central nervous 
system vasculitic involvement and/or the rare hyperviscosity syndrome, 
plasmapheresis may lead to immediate beneficial effects. In general, the 
apheresis should be followed by immunosuppression, in order to avoid post-
apheretic rebound of symptoms. In all cases, a careful clinical monitoring of 
MCs patients is mandatory, with particular attention to metabolic, 
autoimmune, and neoplastic complications [62-66].  
The treatment of MCs associated with malignant lymphoproliferation, mainly 
B-cell NHL, is a priority than of the underlying hematological disorder.  
 
Treatment of cryoglobulinemic skin ulcers  
The updated review of the literature revealed the presence of skin ulcers in 
around a quarter of MCs patients [5]. These are often non-healing cutaneous 
lesions, possibly complicated by local infection and gangrene; moreover, they 
may severely affect the patients’ quality of life and the overall prognosis [67]. 
Therefore, the treatment of cryoglobulinemic skin ulcers is particularly 
challenging in the clinical practice. These lesions are prevalent in the lower 
limbs, where other pathogenetic co-factors may be associated - namely, 
venous insufficiency and/or arteriosclerotic alterations, which are not rare in 
older patients with comorbidities and frequently treated with steroids [67]. 
Figure 5 summarizes the therapeutic strategy for cryoglobulinemic skin ulcers, 
including both systemic (immunosuppressors, corticosteroids, and/or plasma 
exchange) and local treatments [67]. Among systemic treatments, the anti-
CD20 monoclonal antibody rituximab represents one of the most effective and 
frequently employed therapy [55, 56, 59]; while, available data focusing on 
local therapeutic approach are generally limited to anecdotal observations 
[67]. Local treatments consisted of sharp or surgical debridement, as well as 
interactive dressing according to the condition of wound bed, perilesional 
skin, and the possible presence of infection, usually detected in the majority of 
patient with skin ulcers. Analgesic treatment is mandatory for background 
pain due to skin ulcers, as well as for procedural pain; this latter is critical for 
an effective local skin ulcers management. The majority of cryoglobulinemic 
skin ulcers heal at a variable time interval according to the severity of the 
single lesion; only a low percentage of patients with very severe, non-healing 
skin ulcers need amputation [67]. Overall, a trained team of operators with 
specific experience might be involved for an integrated therapeutic approach 
of these very challenging manifestations. 
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 Legend to the Figures 
Fig. 1 Left: etiopathogenetic cascade of MCs. It is a multifactorial and 
multistep process, including HCV infection, predisposing host factors, and 
unknown environmental/toxic triggers. The main consequence is a 'benign' B-
cell proliferation with a variety of autoantibody production, among which 
rheumatoid factor (RF), and cryo- and non-cryoprecipitable immune-
complexes (IC), which may be correlated to various autoimmune disorders, 
including the MCs (or cryoglobulinemic vasculitis). Moreover, the activation 
of Bcl2 proto-oncogene, followed by other genetic aberrations, may lead to 
frank B-cell lymphomas and other malignancies. Both immunological and 
neoplastic disorders show a clinico-serological and pathological overlap. In 
several cases, autoimmune organ-specific manifestations may evolve to 
systemic conditions, and less frequently to malignancies. Conversely, it is not 
rare that patients with malignancies may develop one or more autoimmune 
manifestations. In this context, cryoglobulinemic vasculitis represents a 
crossing road between autoimmune and neoplastic disorders. While the overall 
symptom complex triggered by viral infection may be termed ‘HCV 
syndrome’.  
 
 
 
 
 Fig. 2. Clinico-serological features of MCs. 
HCV: hepatitis C virus; HBV: hepatitis B virus; ANA: antinuclear antibodies: 
ENA: anti-extractable nuclear antigen antibodies; ASMA: anti-smooth muscle 
antibodies  AMA: antimitochondrial antibodies; B-NHL: B-cell non-
Hodgkin’s lymphoma 
 
 
 
 
Fig. 3. Cutaneous manifestations of MCs. 
different skin manifestations of cryoglobulinemic vasculitis:  
a) orthostatic purpura secondary to necrotizing leukocytoclastic vasculitis of 
the skin;  
b) symmetrical hyperpigmentation of the skin on the legs after repeated 
episodes of purpura; both orthostatic purpura and these permanent ochraceous 
lesions represent the typical skin manifestations of CV;  
c-d)  more severe vasculitic manifestations showing multiple skin ulcers with 
the presence of central necrotic tissue and slough  (adherent fibrous material 
derived from proteins, fibrin and fibrinogen) in the wound bed. The presence 
of devitalized tissue acts as a physical barrier to epidermal cell migration and 
healing process; the borders of skin ulcers are irregular and scarcely reactive.  
e) distal gangrene of the second toe of the right foot  
 
 
 
 
Fig. 4. The treatment of mixed cryoglobulinemic syndrome (MCs) may be 
modulated according to the clinical status of individual patients (see text).  
CPX, cyclophosphamide; CS, corticosteroid; LAC, low antigen-content; RTX, 
rituximab. 
 
  
 
 
Fig. 5.  Therapeutic strategy of cryoglobulinemic cutaneous ulcers should be 
based on both systemic and local treatments (see also text). 
After clinical work-up considering the entire MCs, including possible 
comorbidities (venous insuffi ciency and/or arteriosclerotic alterations, 
diabetes, and so on), and careful examination of the ulcer characteristics, the 
systemic treatment may be based on etiological, pathogenetic, and/ or 
symptomatic therapies. More aggressive combined treatments 
(immunosuppressors, steroids, and plasmapheresis) may be necessary in the 
presence of very severe, non-healing skin ulcers. Long-term administration of 
analgesics is often necessary to improve the patient’s chronic pain and 
compliance with local treatment, which should be carried out at a wound care 
clinic. Wound bed preparation, with particular regard to the prevention and 
treatment of infections, is crucial for the healing of cryoglobulinemic skin 
ulcers.	  	  	  

	  
